ClinicalTrials.gg
RecruitingNCT06068361EEG-EDELYUpdated Mar 27, 2025

Diagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach

An observational study in Lewy Bodies Disease, Alzheimer Disease and Cognitive Impairment, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
130
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, 1 of them phase 3. Alzheimer Disease · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
5th of 14
130 · median 97
Started
2024
with 2 others
Observational
14 of 28
4 open now
Registered
23rd of 28
by date

Among the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, this one is the 5th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, and was the 23rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

9 of the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Dementia with Lewy body disease (DLB) is the second leading cause of degenerative cognitive disorder after Alzheimer's disease (AD). Its variable clinical expression makes diagnosis difficult. To date, there is no validated DLB diagnostic biomarker, despite several biomarkers in development (EEG, MRI, biology).

Studies have shown that an improvement in diagnostic performance could be obtained by combining different modalities biomarkers using machine learning.

The aim of this research is to identify the best combination of multimodal biomarkers for the diagnosis of DLB (EEG, MRI, biology, cognitive scores), using a machine learning approach applied to a clinical cohort.

Read the detailed description

Study population: Observational prospective cohort study including over 24 months at the GHU AP-HP. Nord Lariboisière, Cognitive Neurology Center : 50 probable DLB patients, 50 AD patients, and 30 control subjects with subjective cognitive impairment but without any element in favor of neurodegenerative disorders. Total clinical dataset n= 130.

Act :

  • 32-electrode EEG (resting state, passive auditory and active visual task).
  • 4 dry electrode EEG cap simultaneously with the 32-electrode EEG

Expected results: Improved DLB diagnosis performance using a combination of multimodal biomarkers (EEG, cognitive scores, plasma, brain MRI).

03

Conditions studied

  • Lewy Bodies Disease
  • Alzheimer Disease
  • Cognitive Impairment

Keywords

  • EEG
  • MRI
  • Plasma biomarkers
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Observational prospective cohort study included at the GHU AP-HP. Nord Lariboisière, Cognitive Neurology Center : 50 probable DLB patients, 50 AD patients, and 30 control subjects with subjective cognitive impairment but without any element in favor of neurodegenerative disorders

Eligibility criteria

Inclusion Criteria for DLB ant AD patients:

  • Neuropsychological assessment possible (good level in French language, absence of visual/auditory deficit limiting the cognitive assessment)
  • Dementia with Lewy bodies according to the revised criteria of Mc Keith 2017 or probable AD defined according to McKhann 2011 criteria including CSF biomarkers (an abnormal level of beta-amyloid 1-42 protein [Ab42] or a pathological Ab42/Ab40 ratio and an abnormal level of phosphorylated tau [p-tau])

Inclusion Criteria for control patients:

  • Neuropsychological assessment possible (good level in French language, absence of visual/auditory deficit limiting the cognitive assessment)
  • (Mini-mental State Examination) greater than or equal to 28, normal MemScreen test results, normal brain MRI and normal neurological examination

Exclusion Criteria (for all) :

  • to MRI
  • Other neurological or psychiatric or toxic/iatrogenic disorders that may account for the cognitive impairment or for EEG abnormalities
  • Any unstable medical pathology and/or that may account for the cognitive impairment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
130 participants (estimated)
Patient registry
No

Groups and cohorts

  • DLB patients

    Dementia with Lewy bodies according to the revised criteria of Mc Keith 2017

    Diagnostic Test: EEG

  • AD patients

    Alzheimer's disease according to McKhann et al., 2011 criteria including CSF biomarkers (an abnormal level of beta-amyloid 1-42 protein \[Ab42\] or a pathological Ab42/Ab40 ratio and an abnormal level of phosphorylated tau \[p-tau\])

    Diagnostic Test: EEG

  • Control

    Subjective cognitive complaint, with a normal brain MRI and neurological examination, without any elements in favor of a neurodegenerative disease

    Diagnostic Test: EEG

Interventions

  • Diagnostic testEEG

    32-electrode EEG (resting state, passive auditory and active visual task) + simultaneous recording with a 4 dry electrode EEG cap

06

What researchers measure

Primary outcomes

  1. Diagnostic performance of a composite multimodal score

    Diagnostic performance (sensitivity, specificity, accuracy) of a composite multimodal score combining quantitative EEG metrics, plasma biomarkers, MRI volumetric markers and cognitive scores, to differentiate groups of patients (AD, DLB) and control subjects.

    Time frame: 24 month

Secondary outcomes

  1. Comparison between groups of patients and controls of a composite EEG score combining several quantitative EEG parameters.

    Time frame: 24 month

  2. Correlation between EEG parameters, biological biomarkers, MRI volumetric markers and cognitive scores assessed in the three groups (DLB, AD, controls)

    Time frame: 24 month

  3. Reproducibility of 32-electrode EEG results with the 4 dry electrodes EEG cap

    Time frame: 24 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 36 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2023
First posted
Oct 5, 2023
StartActual
Sep 11, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06068361
Collaborators
Association des Aidants et Malades à Corps de Lewy (A2MCL)
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Sep 11, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Mar 27, 2025

Study contacts

Claire PAQUET, MDPhD
Contact
claire.paquet@aphp.fr
0140054313 ext. 33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion